[Breast cancer: adjuvant hormone and chemotherapy].
Indications and types of adjuvant treatment depend on the number of infiltrated axillary lymph nodes, menopausal and hormonal receptor status. In N0 situation is to date no indication for hormonal or cytotoxic therapy outside of clinical trials: disease-free survival may be improved but overall survival is not influenced. In N+ situation premenopausal patients should receive polychemotherapy independent from hormonal receptor status, postmenopausal patients with positive receptor status should be treated with tamoxifen up to 5 years: in this situation disease-free interval and overall survival can be enhanced significantly.
Possinger
K
K
GSF-Institut für Klinische Hämatologie, Klinikum Grosshadern, Universität München.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
D000970:Antineoplastic Agents; D006728:Hormones